Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Advances in Diagnostic and Interventional Radiology in Oncology
share announcement

Advances in Diagnostic and Interventional Radiology in Oncology

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (28 February 2025) | Viewed by 1392

Special Issue Editors

Dr. Eliodoro Faiella

E-Mail Website
Guest Editor
Department of Diagnostic and Interventional Radiology, Departmental Faculty of Medicine and Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy
Interests: interventional radiology; CT scan; magnetic resonance; radiology; diagnostic radiology; computed tomography
Special Issues, Collections and Topics in MDPI journals
Dr. Rosario Francesco Grasso

E-Mail Website
Guest Editor
Departmental Faculty of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128 Rome, Italy
Interests: radiology; ultrasound; imaging; pancreatectomy; angiography; multiple regression analysis; computed tomography; magnetic resonance
Special Issues, Collections and Topics in MDPI journals
Dr. Giuseppina Pacella

E-Mail Website
Guest Editor
Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Rome, Italy
Interests: interventional radiology; computed tomography; magnetic resonance; diagnostic radiology; ultrasonography; angiography; interventional oncology

Special Issue Information

Dear Colleagues,

This Special Issue delves into the latest advancements and innovations in the field of diagnostic and interventional radiology for the management of oncologic conditions.

In the realm of diagnostic radiology, this Special Issue focuses on the remarkable progress made in high-resolution imaging techniques, multimodal image fusion, and the application of artificial intelligence in image analysis. These advancements have significantly enhanced the early detection, precise localization, and accurate diagnosis of tumors. By leveraging these technologies, radiologists can gain a deeper understanding of tumor biology, invasion patterns, and their relationships with surrounding tissues, which is crucial for developing personalized treatment plans.

Interventional radiology focuses on the evolution and impact of minimally invasive therapeutic techniques in oncology. This includes transarterial chemoembolization, ablation techniques (thermal and non-thermal), and particle implantation, among others. These techniques offer a less invasive approach to tumor treatment, effectively destroying cancer cells while minimizing collateral damage to healthy tissue. The Special Issue also highlights the role of interventional radiology in palliative care, pain management, and the management of oncologic complications.

We look forward to receiving your contributions.

Dr. Eliodoro Faiella
Dr. Rosario Francesco Grasso
Dr. Giuseppina Pacella
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diagnostic radiology
  • interventional radiology
  • interventional oncology
  • computed tomography
  • ultrasonography
  • magnetic resonance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

18 pages, 2030 KiB  
Article
Health Outcomes and Resource Consumption Analysis of Radioembolization with Y90 Glass Microspheres (TARE-Y90) Versus Transarterial Chemoembolization with Irinotecan (DEBIRI) in Patients with Liver Metastases from Colorectal Cancer in Spain
by Juan José Ciampi-Dopazo, Gonzalo Ruiz Villaverde, Juan José Espejo, Raúl García Marcos, Daniel Pérez Enguix, Serena Pisoni, José J. Martínez-Rodrigo, Pablo Navarro Vergara, Pedro Pardo Moreno and Antonio Rodríguez-Fernández
Diagnostics 2025, 15(7), 796; https://doi.org/10.3390/diagnostics15070796 - 21 Mar 2025
Viewed by 386
Abstract
Background: The present study aims to investigate the superiority of TARE-Y90 in the treatment of liver metastases from colorectal cancer in comparison to DEBIRI and perform a parallel resource consumption study to demonstrate a possible favorable cost-effectiveness balance. Methods: The number [...] Read more.
Background: The present study aims to investigate the superiority of TARE-Y90 in the treatment of liver metastases from colorectal cancer in comparison to DEBIRI and perform a parallel resource consumption study to demonstrate a possible favorable cost-effectiveness balance. Methods: The number of subjects included in this study was 46 for TARE-Y90 and 56 in the DEBIRI group. The variables of interest in this study were collected for all selected subjects. Time-to-endpoint outcomes (overall survival, time to progression and time to extra-hepatic progression) were calculated by Kaplan–Meier analysis, reported as medians with 95% confidence intervals and compared between groups by log-rank testing. Values for median time-to-event and 95% confidence intervals were calculated using bootstrapping. Results: Categorization into overall response (OR) and no overall response (NOR) revealed a higher percentage of overall responses in the DEBIRI group (52%) compared to TARE-Y90 (24%). The numerical differences observed in certain response categories did not reach statistical significance, indicating a comparable overall response to treatment between the two cohorts based on the m-RECIST criteria. Median overall survival for the TARE-Y90 cohort was 11.3 (95% CI 10.9–18.6) months and 15.8 (95% CI 14.8–22.7) months for the DEBIRI cohort. Log-rank testing showed no statistically significant differences (p = 0.53). Median time to hepatic disease progression for the TARE-Y90 cohort was 3.5 (95% CI 3.4–8.1) months and 3.8 (95% CI 3.7–11.1) months for the DEBIRI cohort. Log-rank testing showed no statistically significant differences (p = 0.82). An important result of the resource utilization analysis is that TARE-Y90 patients had 1.33 treatments on average per patient, while DEBIRI patients had 3.16 treatments per patient. TARE-Y90 patients also needed fewer days of hospitalization than those in the DEBIRI group. The consequence is that the overall use of resources was higher for DEBIRI in comparison to TARE-Y90. Conclusions: Our analysis of the TARE-Y90 and DEBIRI treatments for CRC liver metastases contributes valuable insights into their comparative effectiveness, revealing no significant differences in radiological responses and overall survival. TARE-Y90 showed higher resource utilization, and its potential advantages in patient comfort and average resource consumption per patient warrant consideration. Full article
(This article belongs to the Special Issue Advances in Diagnostic and Interventional Radiology in Oncology)
►▼ Show Figures

Figure 1

Other

Jump to: Research

4 pages, 784 KiB  
Interesting Images
Paradoxical Reaction to Antituberculosis Therapy Mimicking Tumor Progression in Lung Cancer Patient
by Eunkyoung Choi, Yong-An Chung, Ju Sang Kim and Jinkyoung Oh
Diagnostics 2025, 15(4), 472; https://doi.org/10.3390/diagnostics15040472 - 14 Feb 2025
Viewed by 502
Abstract
We describe the case of a 67-year-old man with lung cancer, who developed pulmonary tuberculosis (TB) following chemotherapy and subsequently exhibited a paradoxical reaction on positron emission tomography/computed tomography (PET/CT) after initiating antituberculosis therapy. While pulmonary consolidations improved with antituberculosis treatment, newly detected [...] Read more.
We describe the case of a 67-year-old man with lung cancer, who developed pulmonary tuberculosis (TB) following chemotherapy and subsequently exhibited a paradoxical reaction on positron emission tomography/computed tomography (PET/CT) after initiating antituberculosis therapy. While pulmonary consolidations improved with antituberculosis treatment, newly detected hypermetabolic mediastinal lymph nodes appeared on PET/CT. Based on the clinical course, we provisionally concluded that the mediastinal lymphadenopathy represented a paradoxical reaction. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) confirmed the diagnosis of TB. Clinicians added steroids and continued the antituberculosis medication, and follow-up PET/CT showed complete resolution of these lesions. This case highlights the importance of recognizing paradoxical reactions to antituberculosis therapy, when restaging PET/CT reveals divergent findings, with some tumor foci responding and other lesions appearing to be progressing. Full article
(This article belongs to the Special Issue Advances in Diagnostic and Interventional Radiology in Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop